Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Targets for Cancer Immunotherapy
A. Charles, C. Bourne, S. S. Mun, T. Dao, Z. Aretz, T. Korontsvit, M. Klatt, D. A. Scheinberg
This study shows low-dose CDK4/6 inhibitors increase HLA ligand presentation from cell cycle proteins, creating potential targets for immunotherapy in breast cancer.
bioRxiv · Jun 18, 2020Cancer Biology